Novartis' position about this year's price increase has been announced during the Q2 2018 earnings call transmitted as a live audio webcast.
In response to the heated political rhetoric over the cost of prescription drugs, Novartis has decided not to raise prices on its medicines in the US for the rest of 2018.
The move by Merck comes after Pfizer announced price hikes for almost three dozen drugs only to reverse course amid public pressure from President Donald Trump.
They discussed the Administration's "ongoing commitment to lowering prescription drug prices for American patients", Gidley said.
"We thought that was prudent given the dynamic environment that we're now in. Likewise to Pfizer. We are making a big push to actually reduce the prices, maybe substantially, on prescription drugs", Trump said in a tweet.
Pfizer Inc., on the other hand, spent $1.94 million on Washington lobbying in the second quarter, a 2.1 percent increase in lobbying spending since previous year.
Trio of Liverpool departures on agenda as transfer attention turns to sales
Alisson played a pivotal part in the Roma side which unexpectedly reached the last four of the Champions League last season. Liverpool will be hoping that Alisson is as successful as their last recruit from AS Roma , Mohamed Salah .
Sony Announces 'Amazing Red' Spider-Man PS4 Pro Bundle
However, it seems that Insomniac relented a bit and made a decision to add a version of Steve Ditko's classic Spider-Man's suit. The 1TB PS4 Pro is releasing on September 7th alongside the game with a custom red DualShock 4 complete with white buttons.
Ferrari chief Sergio Marchionne replaced as result of illness
The sports auto maker also announced a replacement, naming Fiat Chrysler chairman John Elkann as his successor. Manley, 54, had been heading the Jeep brand since June 2009 and the Ram brand from October 2015.
In May, the Trump administration outlined a plan for lower prices, but critics have said it did not go far enough.
Last night also Merck & Co responded to the president's appeal.
As for the other six products that Merck said it would take a haircut on, the products are so insignificant that Merck does not even break out sales of the drugs in its Securities and Exchange Commission filings.
Merck plans to lower the prices of seven drugs, including Zepatier, a drug for heaptitis-c, by 60 percent. "We welcome Merck's decision to reduce prices and restrain future price hikes".
On Wednesday, Azar submitted a proposal to the White House that would cut rebates offered to insurers and pharmacy-benefit managers, a measure drug companies have not backed.
Amid a shrinking patient pool and tough competition from companies like Gilead and AbbVie, Zepatier sales were down 65% in the last quarter, to $131 million.